Predicting hepatocellular carcinoma through cross-talk genes identified by risk pathways
Hepatocellular carcinoma (HCC) is the most frequent type of liver cancer with poor survival rate and high mortality. Despite efforts on the mechanism of HCC, new molecular markers are needed for exact diagnosis, evaluation and treatment. Here, we combined transcriptome of HCC with networks and pathways to identify reliable molecular markers. Through integrating 249 differentially expressed genes with syncretic protein interaction networks, we constructed a HCC-specific network, from which we further extracted 480 pivotal genes. Based on the cross-talk between the enriched pathways of the pivotal genes, we finally identified a HCC signature of 45 genes, which could accurately distinguish HCC patients with normal individuals and reveal the prognosis of HCC patients. Among these 45 genes, 15 showed dysregulated expression patterns and a part have been reported to be associated with HCC and/or other cancers. These findings suggested that our identified 45 gene signature could be potential and valuable molecular markers for diagnosis and evaluation of HCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Oncotarget - 9(2018), 30 vom: 20. Apr., Seite 21259-21267 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Lei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cross-talk genes |
|---|
| Anmerkungen: |
Date Revised 14.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.24915 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM284118591 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM284118591 | ||
| 003 | DE-627 | ||
| 005 | 20240314234033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.24915 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1328.xml |
| 035 | |a (DE-627)NLM284118591 | ||
| 035 | |a (NLM)29765536 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Lei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predicting hepatocellular carcinoma through cross-talk genes identified by risk pathways |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Hepatocellular carcinoma (HCC) is the most frequent type of liver cancer with poor survival rate and high mortality. Despite efforts on the mechanism of HCC, new molecular markers are needed for exact diagnosis, evaluation and treatment. Here, we combined transcriptome of HCC with networks and pathways to identify reliable molecular markers. Through integrating 249 differentially expressed genes with syncretic protein interaction networks, we constructed a HCC-specific network, from which we further extracted 480 pivotal genes. Based on the cross-talk between the enriched pathways of the pivotal genes, we finally identified a HCC signature of 45 genes, which could accurately distinguish HCC patients with normal individuals and reveal the prognosis of HCC patients. Among these 45 genes, 15 showed dysregulated expression patterns and a part have been reported to be associated with HCC and/or other cancers. These findings suggested that our identified 45 gene signature could be potential and valuable molecular markers for diagnosis and evaluation of HCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cross-talk genes | |
| 650 | 4 | |a hepatocellular carcinoma (HCC) | |
| 650 | 4 | |a molecular markers | |
| 650 | 4 | |a risk pathways | |
| 700 | 1 | |a Pang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yunfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Zhuo |e verfasserin |4 aut | |
| 700 | 1 | |a Huo, Diwei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Denan |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Hongbo |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jingbo |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qiuqi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiujie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 9(2018), 30 vom: 20. Apr., Seite 21259-21267 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2018 |g number:30 |g day:20 |g month:04 |g pages:21259-21267 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.24915 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2018 |e 30 |b 20 |c 04 |h 21259-21267 | ||